Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI:10.1080/17435889.2024.2368449

Jinhua Dong, Yingying Zhang, Jingsheng Zhou, Shuhui Mao, Jianfen Tang, Suping Li, Qiang Ma, Ling Ai, Wei Wang, Guanghao Zhu, Huijing Shao, Yingdi Meng, Huaiwen Chen, Danqing Chen

{"title":"Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes.","authors":"Jinhua Dong, Yingying Zhang, Jingsheng Zhou, Shuhui Mao, Jianfen Tang, Suping Li, Qiang Ma, Ling Ai, Wei Wang, Guanghao Zhu, Huijing Shao, Yingdi Meng, Huaiwen Chen, Danqing Chen","doi":"10.1080/17435889.2024.2368449","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate a liposome complex conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for the treatment of pre-eclampsia (PE).Methods: In in vitro experiments, the transfection rate, silencing effect and cytotoxicity were determined. In the in vivo PE model, the siRNA distribution, mean arterial pressure, 24-h urine protein concentration, serum sFlt1 concentration, number of viable fetuses and placental weight were measured.Results: The nanomedicine effectively reduced the expression of sFIt1 and had a strong ability to target placental tissues. It could significantly reduce the symptoms of pre-eclampsia and improve pregnancy outcomes in PE model rats.Conclusion: The constructed nanomedicine can improve pregnancy outcomes in a rat model of pre-eclampsia and provides a new strategy for the treatment of pre-eclampsia.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11389737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2368449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate a liposome complex conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for the treatment of pre-eclampsia (PE).Methods: In in vitro experiments, the transfection rate, silencing effect and cytotoxicity were determined. In the in vivo PE model, the siRNA distribution, mean arterial pressure, 24-h urine protein concentration, serum sFlt1 concentration, number of viable fetuses and placental weight were measured.Results: The nanomedicine effectively reduced the expression of sFIt1 and had a strong ability to target placental tissues. It could significantly reduce the symptoms of pre-eclampsia and improve pregnancy outcomes in PE model rats.Conclusion: The constructed nanomedicine can improve pregnancy outcomes in a rat model of pre-eclampsia and provides a new strategy for the treatment of pre-eclampsia.

查看原文本刊更多论文

E-Lip-siRNA-sFlt1 对先兆子痫的治疗效果：靶向基因沉默和改善妊娠结局。

目的：评估一种与抗表皮生长因子受体（EGFR）抗体结合的脂质体复合物用于治疗子痫前期（PE）的效果。研究方法：在体外实验中，研究人员对脂质体复合物与抗表皮生长因子受体（EGFR）抗体的结合率进行了评估：在体外实验中，测定转染率、沉默效果和细胞毒性。在体内子痫模型中，测定 siRNA 分布、平均动脉压、24 小时尿蛋白浓度、血清 sFlt1 浓度、存活胎儿数和胎盘重量。结果显示纳米药物有效降低了 sFIt1 的表达，并具有很强的靶向胎盘组织的能力。它能明显减轻子痫前期症状，改善 PE 模型大鼠的妊娠结局。结论所构建的纳米药物可改善子痫前期模型大鼠的妊娠结局，为治疗子痫前期提供了一种新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量